entrinsic bioscience Secures $49 million in Financing to Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients

– Jefferies acted as sole lender to EBS. Aon Plc, using its proprietary intellectual property (IP) valuation platform to value EBS’ IP portfolio, arranged for an IP Collateral Insurance policy for Jefferies, collateralized by EBS’ IP portfolio.
– EBS is raising $49m in non-dilutive growth capital from Jefferies Group LLC’s subsidiary, Jefferies Funding LLC (Jefferies).
– Following Series A and B raises, including multiple rounds of investment from Johnson & Johnson INNOVATION | JJDC.
– EBS is a leader in functional ingredients and bioactives.